Although the use of digital health technology (DHT) for remote data acquisition may “offer important opportunities in clinical research,” the FDA cautions sponsors, investigators and institutional review boards (IRBs) to “consider any risks to trial participants associated with the use of DHTs for data collection.” An FDA draft guidance released Dec. 23 defines DHTs as system... Read More